A vaginal gel cut of the HIV put drugs into tenofovir can reduce a woman’s chances of being infected through the virus by means of dint of. a male sexual partner, the results of a South African clinical tribulation put in mind of.
“Tenofovir gel could fill an important HIV prevention gap by empowering women who are unable to fortunately treat for mutual faithfulness or condom use with their masculine partners,” said Dr. Quarraisha Abdool Karim, co-principal investigator of the double-blind, randomized control trial, in a news release Monday.
Karim is companion director of the Centre in quest of the AIDS Programme of Research in South Africa (CAPRISA) and join professor of epidemiology at Columbia University in New York.
“This strange technology has the potential to alter the course of the HIV prevalent, especially in southern Africa where young women hold up the brunt of this devastating disease,” Karim said.
The results need to exist confirmed.
Results of the South African trial are being presented at the International AIDS Conference currently infectious place in Vienna and appear in Monday’s online issue of the journal Science.
For the effort, about 445 women believed the tenofovir gel, and 444 received a placebo gel. The women were told to use it 12 hours before sex and as soon as possible not more than 12 hours thereafter.
All participants were assayed for HIV at monthly follow-up visits, at that they also received reproductive freedom from disease services, such as pregnancy tests, and HIV prevention services, including pre- and post-test counseling, HIV risk-reduction counseling, condoms and treatment for other sexually transmitted infections.
Adherence questions
At the period of the study, there were 38 HIV infections amidst the microbicide group compared by 60 in the other group.
About 40 per cent of the women in the trial had below 50 per cent tenacity, that points to a need to enhance and objectively measure for what reason closely women followed instructions about using the gel, the think respecting’sitting authors said.
Mild diarrhea was slightly more common among those using the gel.
The effectiveness of the gel seemed to decline after 18 months, which needs to subsist investigated further, the researchers said.
The gel is not turn to account commercially. It was made against this and not the same ongoing investigation by California-based Gilead Sciences Inc., which sells tenofovir as a pill.
Gilead has licensed the rights to produce the gel royalty-free in the world’session 95 poorest countries, reported Dr. Howard Jaffe, president of the Gilead Foundation, the company’session philanthropic arm.
The application of mind was sponsored through CAPRISA; Family Health International; CONRAD, an AIDS research effort based at Eastern Virginia Medical School; and the U.S. Agency for International Development, or USAID.
With files from The Associated Press